ID   UBP33_HUMAN             Reviewed;         942 AA.
AC   Q8TEY7; Q8TEY6; Q96AV6; Q9H9F0; Q9UPQ5;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   28-JUN-2023, entry version 184.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 33;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme 33;
DE   AltName: Full=Ubiquitin thioesterase 33;
DE   AltName: Full=Ubiquitin-specific-processing protease 33;
DE   AltName: Full=VHL-interacting deubiquitinating enzyme 1;
DE            Short=hVDU1;
GN   Name=USP33; Synonyms=KIAA1097, VDU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), UBIQUITINATION, INTERACTION
RP   WITH VHL, AND TISSUE SPECIFICITY.
RX   PubMed=11739384; DOI=10.1074/jbc.m108269200;
RA   Li Z., Na X., Wang D., Schoen S.R., Messing E.M., Wu G.;
RT   "Ubiquitination of a novel deubiquitinating enzyme requires direct binding
RT   to von Hippel-Lindau tumor suppressor protein.";
RL   J. Biol. Chem. 277:4656-4662(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH DIO2.
RX   PubMed=12865408; DOI=10.1172/jci18348;
RA   Curcio-Morelli C., Zavacki A.M., Christofollete M., Gereben B.,
RA   de Freitas B.C., Harney J.W., Li Z., Wu G., Bianco A.C.;
RT   "Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau
RT   protein-interacting deubiquitinating enzymes regulates thyroid hormone
RT   activation.";
RL   J. Clin. Invest. 112:189-196(2003).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   INTERACTION WITH SELENBP1, AND SUBCELLULAR LOCATION.
RX   PubMed=19118533; DOI=10.1016/j.bbrc.2008.12.110;
RA   Jeong J.Y., Wang Y., Sytkowski A.J.;
RT   "Human selenium binding protein-1 (hSP56) interacts with VDU1 in a
RT   selenium-dependent manner.";
RL   Biochem. Biophys. Res. Commun. 379:583-588(2009).
RN   [9]
RP   FUNCTION, INTERACTION WITH ADRB2, AND MUTAGENESIS OF CYS-194 AND HIS-673.
RX   PubMed=19424180; DOI=10.1038/emboj.2009.128;
RA   Berthouze M., Venkataramanan V., Li Y., Shenoy S.K.;
RT   "The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor
RT   recycling and resensitization.";
RL   EMBO J. 28:1684-1696(2009).
RN   [10]
RP   FUNCTION, INTERACTION WITH ARRB1 AND ARRB2, AND MUTAGENESIS OF CYS-194 AND
RP   HIS-673.
RX   PubMed=19363159; DOI=10.1073/pnas.0901083106;
RA   Shenoy S.K., Modi A.S., Shukla A.K., Xiao K., Berthouze M., Ahn S.,
RA   Wilkinson K.D., Miller W.E., Lefkowitz R.J.;
RT   "Beta-arrestin-dependent signaling and trafficking of 7-transmembrane
RT   receptors is reciprocally regulated by the deubiquitinase USP33 and the E3
RT   ligase Mdm2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6650-6655(2009).
RN   [11]
RP   ALTERNATIVE SPLICING (ISOFORM 3), AND SUBCELLULAR LOCATION.
RX   PubMed=21801292; DOI=10.1111/j.1600-0854.2011.01261.x;
RA   Thorne C., Eccles R.L., Coulson J.M., Urbe S., Clague M.J.;
RT   "Isoform-specific localization of the deubiquitinase USP33 to the Golgi
RT   apparatus.";
RL   Traffic 12:1563-1574(2011).
RN   [12]
RP   INTERACTION WITH ADRB2.
RX   PubMed=23166351; DOI=10.1083/jcb.201208192;
RA   Han S.O., Xiao K., Kim J., Wu J.H., Wisler J.W., Nakamura N.,
RA   Freedman N.J., Shenoy S.K.;
RT   "MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound
RT   beta(2)-adrenergic receptors.";
RL   J. Cell Biol. 199:817-830(2012).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CCP110, DEVELOPMENTAL
RP   STAGE, AND MUTAGENESIS OF CYS-194 AND HIS-673.
RX   PubMed=23486064; DOI=10.1038/nature11941;
RA   Li J., D'Angiolella V., Seeley E.S., Kim S., Kobayashi T., Fu W.,
RA   Campos E.I., Pagano M., Dynlacht B.D.;
RT   "USP33 regulates centrosome biogenesis via deubiquitination of the
RT   centriolar protein CP110.";
RL   Nature 495:255-259(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   STRUCTURE BY NMR OF 36-130, ZINC-BINDING, AND DOMAIN UBP-TYPE ZINC FINGER.
RX   PubMed=17766394; DOI=10.1110/ps.072967807;
RA   Allen M.D., Bycroft M.;
RT   "The solution structure of the ZnF UBP domain of USP33/VDU1.";
RL   Protein Sci. 16:2072-2075(2007).
CC   -!- FUNCTION: Deubiquitinating enzyme involved in various processes such as
CC       centrosome duplication, cellular migration and beta-2 adrenergic
CC       receptor/ADRB2 recycling. Involved in regulation of centrosome
CC       duplication by mediating deubiquitination of CCP110 in S and G2/M
CC       phase, leading to stabilize CCP110 during the period which centrioles
CC       duplicate and elongate. Involved in cell migration via its interaction
CC       with intracellular domain of ROBO1, leading to regulate the Slit
CC       signaling. Plays a role in commissural axon guidance cross the ventral
CC       midline of the neural tube in a Slit-dependent manner, possibly by
CC       mediating the deubiquitination of ROBO1. Acts as a regulator of G-
CC       protein coupled receptor (GPCR) signaling by mediating the
CC       deubiquitination of beta-arrestins (ARRB1 and ARRB2) and beta-2
CC       adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling
CC       and resensitization after prolonged agonist stimulation by
CC       constitutively binding ADRB2, mediating deubiquitination of ADRB2 and
CC       inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is
CC       probably transferred to the translocated beta-arrestins, leading to
CC       beta-arrestins deubiquitination and disengagement from ADRB2. This
CC       suggests the existence of a dynamic exchange between the ADRB2 and
CC       beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid
CC       hormone regulation. Mediates deubiquitination of both 'Lys-48'- and
CC       'Lys-63'-linked polyubiquitin chains. {ECO:0000269|PubMed:12865408,
CC       ECO:0000269|PubMed:19363159, ECO:0000269|PubMed:19424180,
CC       ECO:0000269|PubMed:23486064}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- SUBUNIT: Interacts with VHL, leading to its ubiquitination and
CC       subsequent degradation (PubMed:11739384). Interacts with ARRB1 and
CC       ARRB2 (PubMed:19363159). Interacts with ADRB2 (PubMed:19424180).
CC       Interacts with DIO2 (PubMed:12865408). Interacts with ROBO1. Interacts
CC       with SELENBP1; in a selenium-dependent manner (PubMed:19118533).
CC       Interacts with CCP110 (PubMed:23486064). Interacts with ADRB2
CC       (PubMed:23166351). {ECO:0000269|PubMed:11739384,
CC       ECO:0000269|PubMed:12865408, ECO:0000269|PubMed:19118533,
CC       ECO:0000269|PubMed:19363159, ECO:0000269|PubMed:19424180,
CC       ECO:0000269|PubMed:23166351, ECO:0000269|PubMed:23486064}.
CC   -!- INTERACTION:
CC       Q8TEY7-2; Q13228: SELENBP1; NbExp=5; IntAct=EBI-719307, EBI-711619;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:19118533}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:23486064}.
CC       Note=Associates with centrosomes predominantly in S and G2 phases but
CC       less in G1 phase (PubMed:23486064). {ECO:0000269|PubMed:23486064}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Golgi apparatus
CC       {ECO:0000269|PubMed:21801292}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8TEY7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TEY7-2; Sequence=VSP_008591;
CC       Name=3;
CC         IsoId=Q8TEY7-3; Sequence=VSP_008592, VSP_008593, VSP_008594;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:11739384}.
CC   -!- DEVELOPMENTAL STAGE: Increased expression in S and early G2 phases and
CC       lower levels in late G2 and M phases. {ECO:0000269|PubMed:23486064}.
CC   -!- DOMAIN: The UBP-type zinc finger binds 3 zinc ions. However, it does
CC       not bind ubiquitin, probably because the conserved Arg in position 86
CC       is replaced by a Glu residue. {ECO:0000269|PubMed:17766394}.
CC   -!- PTM: Ubiquitinated via a VHL-dependent pathway for proteasomal
CC       degradation. {ECO:0000269|PubMed:11739384}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. USP20/USP33 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA83049.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF383172; AAL78314.1; -; mRNA.
DR   EMBL; AF383173; AAL78315.1; -; mRNA.
DR   EMBL; AB029020; BAA83049.1; ALT_INIT; mRNA.
DR   EMBL; AK022864; BAB14279.1; -; mRNA.
DR   EMBL; AC114487; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC016663; AAH16663.1; -; mRNA.
DR   CCDS; CCDS678.1; -. [Q8TEY7-1]
DR   CCDS; CCDS679.1; -. [Q8TEY7-2]
DR   CCDS; CCDS680.1; -. [Q8TEY7-3]
DR   RefSeq; NP_055832.3; NM_015017.4. [Q8TEY7-1]
DR   RefSeq; NP_963918.1; NM_201624.2. [Q8TEY7-2]
DR   RefSeq; NP_963920.1; NM_201626.2. [Q8TEY7-3]
DR   PDB; 2UZG; NMR; -; A=36-130.
DR   PDBsum; 2UZG; -.
DR   AlphaFoldDB; Q8TEY7; -.
DR   SMR; Q8TEY7; -.
DR   BioGRID; 116671; 134.
DR   CORUM; Q8TEY7; -.
DR   DIP; DIP-48942N; -.
DR   IntAct; Q8TEY7; 29.
DR   MINT; Q8TEY7; -.
DR   STRING; 9606.ENSP00000359829; -.
DR   MEROPS; C19.037; -.
DR   iPTMnet; Q8TEY7; -.
DR   PhosphoSitePlus; Q8TEY7; -.
DR   SwissPalm; Q8TEY7; -.
DR   BioMuta; USP33; -.
DR   DMDM; 116242838; -.
DR   EPD; Q8TEY7; -.
DR   jPOST; Q8TEY7; -.
DR   MassIVE; Q8TEY7; -.
DR   MaxQB; Q8TEY7; -.
DR   PaxDb; Q8TEY7; -.
DR   PeptideAtlas; Q8TEY7; -.
DR   ProteomicsDB; 74526; -. [Q8TEY7-1]
DR   ProteomicsDB; 74527; -. [Q8TEY7-2]
DR   ProteomicsDB; 74528; -. [Q8TEY7-3]
DR   Antibodypedia; 33489; 308 antibodies from 32 providers.
DR   DNASU; 23032; -.
DR   Ensembl; ENST00000357428.5; ENSP00000350009.1; ENSG00000077254.14. [Q8TEY7-1]
DR   Ensembl; ENST00000370792.7; ENSP00000359828.3; ENSG00000077254.14. [Q8TEY7-3]
DR   Ensembl; ENST00000370793.5; ENSP00000359829.1; ENSG00000077254.14. [Q8TEY7-1]
DR   Ensembl; ENST00000370794.7; ENSP00000359830.3; ENSG00000077254.14. [Q8TEY7-2]
DR   GeneID; 23032; -.
DR   KEGG; hsa:23032; -.
DR   MANE-Select; ENST00000370794.7; ENSP00000359830.3; NM_201624.3; NP_963918.1. [Q8TEY7-2]
DR   UCSC; uc001dht.5; human. [Q8TEY7-1]
DR   AGR; HGNC:20059; -.
DR   CTD; 23032; -.
DR   DisGeNET; 23032; -.
DR   GeneCards; USP33; -.
DR   HGNC; HGNC:20059; USP33.
DR   HPA; ENSG00000077254; Low tissue specificity.
DR   MIM; 615146; gene.
DR   neXtProt; NX_Q8TEY7; -.
DR   OpenTargets; ENSG00000077254; -.
DR   PharmGKB; PA134955343; -.
DR   VEuPathDB; HostDB:ENSG00000077254; -.
DR   eggNOG; KOG1870; Eukaryota.
DR   GeneTree; ENSGT00940000157311; -.
DR   HOGENOM; CLU_004896_0_0_1; -.
DR   InParanoid; Q8TEY7; -.
DR   OrthoDB; 227085at2759; -.
DR   PhylomeDB; Q8TEY7; -.
DR   TreeFam; TF352179; -.
DR   PathwayCommons; Q8TEY7; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-9010553; Regulation of expression of SLITs and ROBOs.
DR   SignaLink; Q8TEY7; -.
DR   BioGRID-ORCS; 23032; 13 hits in 1209 CRISPR screens.
DR   ChiTaRS; USP33; human.
DR   EvolutionaryTrace; Q8TEY7; -.
DR   GeneWiki; USP33; -.
DR   GenomeRNAi; 23032; -.
DR   Pharos; Q8TEY7; Tbio.
DR   PRO; PR:Q8TEY7; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q8TEY7; protein.
DR   Bgee; ENSG00000077254; Expressed in cerebellar vermis and 210 other tissues.
DR   ExpressionAtlas; Q8TEY7; baseline and differential.
DR   Genevisible; Q8TEY7; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030891; C:VCB complex; TAS:UniProtKB.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IDA:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IMP:UniProtKB.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IPI:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0051298; P:centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0032091; P:negative regulation of protein binding; IMP:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:CACAO.
DR   GO; GO:0010506; P:regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:UniProtKB.
DR   CDD; cd02674; Peptidase_C19R; 1.
DR   Gene3D; 3.90.70.10; Cysteine proteinases; 2.
DR   Gene3D; 3.30.2230.10; DUSP-like; 2.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR035927; DUSP-like_sf.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR006615; Pept_C19_DUSP.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR001607; Znf_UBP.
DR   PANTHER; PTHR21646; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE; 1.
DR   PANTHER; PTHR21646:SF32; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 33; 1.
DR   Pfam; PF06337; DUSP; 2.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF02148; zf-UBP; 1.
DR   SMART; SM00695; DUSP; 2.
DR   SMART; SM00290; ZnF_UBP; 1.
DR   SUPFAM; SSF54001; Cysteine proteinases; 1.
DR   SUPFAM; SSF143791; DUSP-like; 2.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS51283; DUSP; 2.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
DR   PROSITE; PS50271; ZF_UBP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Cytoskeleton; Endocytosis;
KW   Golgi apparatus; Hydrolase; Metal-binding; Phosphoprotein; Protease;
KW   Reference proteome; Repeat; Thiol protease; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..942
FT                   /note="Ubiquitin carboxyl-terminal hydrolase 33"
FT                   /id="PRO_0000080664"
FT   DOMAIN          185..715
FT                   /note="USP"
FT   DOMAIN          717..810
FT                   /note="DUSP 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00613"
FT   DOMAIN          818..921
FT                   /note="DUSP 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00613"
FT   ZN_FING         37..140
FT                   /note="UBP-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   REGION          294..357
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          419..469
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        317..354
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        419..440
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        194
FT                   /note="Nucleophile"
FT   ACT_SITE        673
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10092,
FT                   ECO:0000255|PROSITE-ProRule:PRU10093"
FT   BINDING         39
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         41
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         61
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         64
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         74
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         79
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         84
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         91
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         95
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         101
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         114
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   BINDING         117
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00502"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         1..31
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10470851,
FT                   ECO:0000303|PubMed:11739384"
FT                   /id="VSP_008591"
FT   VAR_SEQ         552..559
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008592"
FT   VAR_SEQ         834..836
FT                   /note="LNR -> VKK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008593"
FT   VAR_SEQ         837..942
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_008594"
FT   MUTAGEN         194
FT                   /note="C->S: Abolishes deubiquitinating activity. Does not
FT                   inhibit lysosomal trafficking of ADRB2; when associated
FT                   with Q-673."
FT                   /evidence="ECO:0000269|PubMed:19363159,
FT                   ECO:0000269|PubMed:19424180, ECO:0000269|PubMed:23486064"
FT   MUTAGEN         673
FT                   /note="H->Q: Abolishes deubiquitinating activity. Does not
FT                   inhibit lysosomal trafficking of ADRB2; when associated
FT                   with S-194."
FT                   /evidence="ECO:0000269|PubMed:19363159,
FT                   ECO:0000269|PubMed:19424180, ECO:0000269|PubMed:23486064"
FT   CONFLICT        241
FT                   /note="H -> Y (in Ref. 1; AAL78314/AAL78315 and 2;
FT                   BAA83049)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        428
FT                   /note="S -> L (in Ref. 3; BAB14279)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        617
FT                   /note="K -> R (in Ref. 3; BAB14279)"
FT                   /evidence="ECO:0000305"
FT   HELIX           40..44
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   HELIX           50..56
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   TURN            57..59
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   STRAND          62..64
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   TURN            86..89
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   HELIX           91..98
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   STRAND          103..106
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   TURN            107..110
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   STRAND          111..114
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   TURN            115..118
FT                   /evidence="ECO:0007829|PDB:2UZG"
FT   STRAND          119..121
FT                   /evidence="ECO:0007829|PDB:2UZG"
SQ   SEQUENCE   942 AA;  106727 MW;  10A3AD632B901A74 CRC64;
     MTGSNSHITI LTLKVLPHFE SLGKQEKIPN KMSAFRNHCP HLDSVGEITK EDLIQKSLGT
     CQDCKVQGPN LWACLENRCS YVGCGESQVD HSTIHSQETK HYLTVNLTTL RVWCYACSKE
     VFLDRKLGTQ PSLPHVRQPH QIQENSVQDF KIPSNTTLKT PLVAVFDDLD IEADEEDELR
     ARGLTGLKNI GNTCYMNAAL QALSNCPPLT QFFLDCGGLA RTDKKPAICK SYLKLMTELW
     HKSRPGSVVP TTLFQGIKTV NPTFRGYSQQ DAQEFLRCLM DLLHEELKEQ VMEVEEDPQT
     ITTEETMEED KSQSDVDFQS CESCSNSDRA ENENGSRCFS EDNNETTMLI QDDENNSEMS
     KDWQKEKMCN KINKVNSEGE FDKDRDSISE TVDLNNQETV KVQIHSRASE YITDVHSNDL
     STPQILPSNE GVNPRLSASP PKSGNLWPGL APPHKKAQSA SPKRKKQHKK YRSVISDIFD
     GTIISSVQCL TCDRVSVTLE TFQDLSLPIP GKEDLAKLHS SSHPTSIVKA GSCGEAYAPQ
     GWIAFFMEYV KRFVVSCVPS WFWGPVVTLQ DCLAAFFARD ELKGDNMYSC EKCKKLRNGV
     KFCKVQNFPE ILCIHLKRFR HELMFSTKIS THVSFPLEGL DLQPFLAKDS PAQIVTYDLL
     SVICHHGTAS SGHYIAYCRN NLNNLWYEFD DQSVTEVSES TVQNAEAYVL FYRKSSEEAQ
     KERRRISNLL NIMEPSLLQF YISRQWLNKF KTFAEPGPIS NNDFLCIHGG VPPRKAGYIE
     DLVLMLPQNI WDNLYSRYGG GPAVNHLYIC HTCQIEAEKI EKRRKTELEI FIRLNRAFQK
     EDSPATFYCI SMQWFREWES FVKGKDGDPP GPIDNTKIAV TKCGNVMLRQ GADSGQISEE
     TWNFLQSIYG GGPEVILRPP VVHVDPDILQ AEEKIEVETR SL
//
